a 2017 0068

The invention relates to pharmaceutical chemistry and can be used in the development of new agents for the treatment of tuberculosis of the 1,2,4-triazole class.

Summary of the invention consists in that it is proposed as antituberculous agent the (Z)-4,4-dimethyl-1-(4-nitrophenyl)-2-(1*H*-1,2,4-triazol-1-yl)pent-1-en-3-one with the formula:



The compound exhibits antituberculous activity against *Mycobacterium tuberculosis* $H_{37}R_v$ (ATCC 27294) comparable to rifampicin.

The isomeric compound is obtained by selective aldol-crotonic condensation of 3,3-dimethyl-1-(1*H*-1,2,4-triazol-1-yl)butan-2-one with 4-nitrobenzaldehyde, which occurs du-ring reflux in benzene, with azeotropic distillation of the formed water, in the presence of a piperidine-acetic acid catalyst (70%, m.p. 114…116°C).

Claims: 1